"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
There are no known cases of overdosage with Varithena™. In clinical studies, total volumes of up to 60 mL of Varithena™ per treatment session have been administered.
Additional Varithena Information
Report Problems to the Food and Drug Administration
Find out what women really need.